BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

Por Sullivan, Ryan J., Flaherty, Keith T.
Publicado em 2011

Understanding the biology of melanoma and therapeutic implications

Por Sullivan, Ryan J, Fisher, David E
Publicado em 2014

Targeted therapy in Kaposi sarcoma

Por Sullivan, Ryan J., Pantanowitz, Liron, Dezube, Bruce J.
Publicado em 2009

An inexpensive, specific and highly sensitive protocol to detect the Braf(V600E) mutation in melanoma tumor biopsies and blood

Por Panka, David J, Sullivan, Ryan J, Mier, James W
Publicado em 2010

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be

Por Sullivan, Ryan J., LoRusso, Patricia M., Flaherty, Keith T.
Publicado em 2013

Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer

Por Miller, Miles A., Sullivan, Ryan J., Lauffenburger, Douglas A.
Publicado no Clin Cancer Res (2016)

Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy

Por Tseng, Diane, Mason, Xenos L., Neilan, Tomas G., Sullivan, Ryan J.
Publicado no Oncologist (2016)

Epidemiology, pathophysiology and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease

Por Sullivan, Ryan J., Pantanowitz, Liron, Casper, Corey, Stebbing, Justin, Dezube, Bruce J.
Publicado em 2008

Residual hemothorax after chest tube placement correlates with increased risk of empyema following traumatic injury

Por Karmy-Jones, Riyad, Holevar, Michele, Sullivan, Ryan J, Fleisig, Ani, Jurkovich, Gregory J
Publicado em 2008

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

Por Fofaria, Neel M., Frederick, Dennie T., Sullivan, Ryan J., Flaherty, Keith T., Srivastava, Sanjay K.
Publicado no Oncotarget (2015)

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

Por Wargo, Jennifer A., Reuben, Alexandre, Cooper, Zachary A., Oh, Kevin S., Sullivan, Ryan J.
Publicado no Semin Oncol (2015)

Melanoma driver mutations and immune therapy

Por Johnson, Douglas B., Lovly, Christine M., Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.
Publicado no Oncoimmunology (2016)

Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood

Por Gee, Michael S., Ghazani, Arezou A., Haq, Rizwan, Wargo, Jennifer A., Sebas, Matthew, Sullivan, Ryan J., Lee, Hakho, Weissleder, Ralph
Publicado no Nanomedicine (2016)

Utility of 3-year Torso CT and Head Imaging in Asymptomatic Patients with High-Risk Melanoma

Por DeRose, Erin R., Pleet, Alexander, Wang, Wei, Seery, Virginia J., Lee, Mee Young, Renzi, Sharon, Sullivan, Ryan J., Atkins, Michael B.
Publicado em 2011

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

Por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado em 2013

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Por Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Publicado no Oncologist (2015)

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-depende...

Por Kefford, Richard, Sullivan, Ryan J, Miller, Wilson H, Elez, Elena M, Tan, Daniel, Kim, Kevin B, Long, Georgina V, Flaherty, Keith T, Tai, David, Stutvoet, Simone, Maacke, Heiko, Whiley, Matt, Parseval, Laure Moutouh-de, Tabernero, Josep
Publicado em 2014

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

Por Shen, Che-Hung, Kim, Sun Hye, Trousil, Sebastian, Frederick, Dennie T., Piris, Adriano, Yuan, Ping, Cai, Li, Gu, Lei, Li, Man, Lee, Jung Hyun, Mitra, Devarati, Fisher, David E., Sullivan, Ryan J., Flaherty, Keith T., Zheng, Bin
Publicado no Nat Med (2016)

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases is a Post-Translational Mechanism of Kinase Inhibitor Resistance

Por Miller, Miles A., Oudin, Madeleine J., Sullivan, Ryan J., Wang, Stephanie J., Meyer, Aaron S., Im, Hyungsoon, Frederick, Dennie T., Tadros, Jenny, Griffith, Linda G., Lee, Hakho, Weissleder, Ralph, Flaherty, Keith T., Gertler, Frank B., Lauffenburger, Douglas A.
Publicado no Cancer Discov (2016)

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma

Por Lubitz, Carrie C., Parangi, Sareh, Holm, Tammy M., Bernasconi, M. Jordana, Schalck, Aislyn P., Suh, Hyunsuk, Economopoulos, Konstantinos P., Gunda, Viswanath, Donovan, Samuel E., Sadow, Peter M., Wirth, Lori J., Sullivan, Ryan J., Panka, David J.
Publicado no J Mol Diagn (2016)